spacer spacer


C. Blake Gilks

Department of Pathology and Laboratory Medicine
Faculty of Medicine
Professor since July 2005


BSc (University of New Brunswick 1975-78)
M.D. cum laude Medicine (Dalhousie University 1978-82)
Rotating Internship (Royal Columbian Hospital 1982-83)
Resident Anatomic Pathology (University of British Columbia 1985-88)
Fellow Pathology (Harvard University 1988)
Fellow Pathology (Fox Chase Cancer Centre, Philadelphia 1989-91)

Special Professional Qualifications

Fellow of the Royal College of Physicians and Surgeons of Canada (Anatomical Pathology)


Mel Bernstein Award for Resident Teaching, 1994 Roberta Miller Award for ďOutstanding Professional Role ModelĒ, Pathology and Lab Medicine Residency Program, 1998


(a) Journals

  1. Singh N, Gilks CB, Huntsman DG, Smith JH, Coutts M, Ganesan R, McCluggage WG. (2014-04-01). Adult granulosa cell tumour-like areas occurring in ovarian epithelial neoplasms: report of a case series with investigation of FOXL2 mutation status. Histopathology. 64(5),626
  2. Bookman MA, Gilks CB, Kohn EC, Kaplan KO, Huntsman D, Aghajanian C, Birrer MJ, Ledermann JA, Oza AM, Swenerton KD. (2014-03-13). Better Therapeutic Trials in Ovarian Cancer. J Natl Cancer Inst. 0(0),0
  3. Aulmann S, Sinn HP, Penzel R, Gilks CB, Schott S, Hassel JC, Schmidt D, Kommoss F, Schirmacher P, Kommoss S. (2014-03-07). Comparison of molecular abnormalities in vulvar and vaginal melanomas. Mod Pathol. 0(0),0
  4. Hoang LN, Han G, McConechy M, Lau S, Chow C, Gilks CB, Huntsman DG, Köbel M, Lee CH. (2014-03-01). Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor. Histopathology. 64(4),585
  5. Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS. (2014-02-22). A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. BMC Cancer. 14(1),120
  6. Allo G, Bernardini MQ, Wu RC, Shih IM, Kalloger S, Pollett A, Gilks CB, Clarke BA. (2014-02-01). ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Mod Pathol. 27(2),255
  7. Kommoss S, Gilks CB, Penzel R, Herpel E, Mackenzie R, Huntsman D, Schirmacher P, Anglesio M, Schmidt D, Kommoss F. (2014-02-01). A current perspective on the pathological assessment of FOXL2 in adult-type granulosa cell tumours of the ovary. Histopathology. 64(3),380
  8. McAlpine JN, Hanley GE, Woo MM, Tone AA, Rozenberg N, Swenerton KD, Gilks CB, Finlayson SJ, Huntsman DG, Miller DM; Ovarian Cancer Research Program of British Columbia. (2014-01-09). Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol. 0(0),0
  9. McConechy MK, Ding J, Senz J, Yang W, Melnyk N, Tone AA, Prentice LM, Wiegand KC, McAlpine JN, Shah SP, Lee CH, Goodfellow PJ, Gilks CB, Huntsman DG. (2014-01-01). Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Mod Pathol. 27(1),128
  10. Köbel M, Bak J, Bertelsen BI, Carpen O, Grove A, Hansen ES, Levin Jakobsen AM, Lidang M, Måsbӓck A, Tolf A, Gilks CB, Carlson JW. (2013-12-11). Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. Histopathology. 0(0),0
  11. Ervine A, Leung S, Gilks CB, McCluggage WG. (2013-11-23). Thyroid transcription factor-1 (TTF-1) immunoreactivity is an adverse prognostic factor in endometrioid adenocarcinoma of the uterine corpus. Histopathology. 0(0),0
  12. Delair D, Han G, Irving JA, Leung S, Ewanowich CA, Longacre TA, Gilks CB, Soslow RA. (2013-11-01). HNF-1β in Ovarian Carcinomas With Serous and Clear Cell Change. Int J Gynecol Pathol. 32(6),541
  13. Ali RH, Kalloger SE, Santos JL, Swenerton KD, Gilks CB. (2013-11-01). Stage II to IV Low-grade Serous Carcinoma of the Ovary Is Associated With a Poor Prognosis: A Clinicopathologic Study of 32 Patients From a Population-based Tumor Registry. Int J Gynecol Pathol. 32(6),529
  14. Kommoss S, Gilks CB, Kommoss F, Chow C, Hilpert F, du Bois A, Köbel M, Huntsman DG, Anglesio M, Kalloger SE, Pfisterer J. (2013-11-01). Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review. Histopathology. 63(5),704
  15. Chui MH, Gilks CB, Cooper K, Clarke BA. (2013-11-01). Identifying Lynch syndrome in patients with ovarian carcinoma: the significance of tumor subtype. Adv Anat Pathol. 20(6),378
  16. Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, Rosner J, Shumansky K, Kalloger S, Senz J, Yang W, McConechy M, Melnyk N, Anglesio M, Luk MT, Tse K, Zeng T, Moore R, Zhao Y, Marra MA, Gilks B, Yip S, Huntsman DG, McAlpine JN, Shah SP. (2013-09-01). Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol. 231(1),21
  17. McCluggage WG, Singh N, Kommoss S, Huntsman DG, Gilks CB. (2013-09-01). Ovarian Cellular Fibromas Lack FOXL2 Mutations: A Useful Diagnostic Adjunct in the Distinction From Diffuse Adult Granulosa Cell Tumor. Am J Surg Pathol. 37(9),1450
  18. McCluggage WG, Staats PN, Gilks CB, Clement PB, Young RH. (2013-09-01). Luteinized Thecomas (Thecomatosis) Associated With Sclerosing Peritonitis Exhibit Positive Staining With Sex Cord Markers Steroidogenic Factor-1 (SF-1) and FOXL2. Am J Surg Pathol. 37(9),1458
  19. Hoang LN, McConechy MK, Köbel M, Han G, Rouzbahman M, Davidson B, Irving J, Ali RH, Leung S, McAlpine JN, Oliva E, Nucci MR, Soslow RA, Huntsman DG, Gilks CB, Lee CH. (2013-09-01). Histotype-Genotype Correlation in 36 High-grade Endometrial Carcinomas. Am J Surg Pathol. 37(9),1421
  20. Kumar A, Gilks CB, Mar C, Santos J, Tinker AV. (2013-08-03). Patterns of spread of clear cell ovarian cancer: Case report and case series. Gynecol Oncol Case Rep. 6(0),25
  21. Koebel M, Kalloger S, Lee S, Duggan MA, Kelemen LE, Prentice L, Kalli KR, Fridley BL, Visscher DW, Keeney GA, Vierkant RA, Cunningham JM, Chow C, Ness RB, Moysich KB, Edwards RP, Modugno F, Bunker CH, Wozniak EL, Benjamin E, Gayther SA, Gentry-Maharaj A, Menon U, Gilks B, Huntsman DG, Ramus SJ, Goode EL. (2013-07-23). Biomarker-based ovarian carcinoma typing: a histological investigation in the Ovarian Tumor Tissue Analysis consortium. Cancer Epidemiol Biomarkers Prev. 22(10),1677
  22. Sieh W, Köbel M, Longacre TA, Bowtell DD, Defazio A, Goodman MT, Høgdall E, Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke BA, Menon U, Gilks CB, Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkens LR, Carney ME, Thompson PJ, Matsuno RK, Kjær SK, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, García-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bshara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittemore AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ. (2013-07-08). Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol. 14(9),853
  23. Chen ZW, Neufeld H, Copete MA, Garratt J, Gilks CB, Torlakovic EE. (2013-07-01). Academic and Nonacademic Laboratories Perform Equally on CIQC Immunohistochemistry Proficiency Testing. Am J Clin Pathol. 140(1),55
  24. Miller DM, McAlpine JN, Gilks CB, Huntsman DG. (2013-06-01). Opportunistic salpingectomy: the way forward-response to Steven Narod. Curr Oncol. 20(3),143
  25. Sandoval C, Fung-Kee-Fung M, Gilks B, Murphy KJ, Rahal R, Bryant H. (2013-06-01). Examining the use of salpingectomy with hysterectomy in Canada. Curr Oncol. 20(3),173
  26. Gilks CB, Miller D. (2013-06-01). Opportunistic salpingectomy for women at low risk for development of ovarian carcinoma: the time has come. Gynecol Oncol. 129(3),443
  27. Gilks CB, Oliva E, Soslow RA. (2013-06-01). Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am J Surg Pathol. 37(6),874
  28. Lim D, Alvarez T, Nucci MR, Gilks B, Longacre T, Soslow RA, Oliva E. (2013-05-01). Interobserver variability in the interpretation of tumor cell necrosis in uterine leiomyosarcoma. Am J Surg Pathol. 37(5),650
  29. Diep CH, Charles NJ, Gilks CB, Kalloger SE, Argenta PA, Lange CA. (2013-04-10). Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells. Cell Cycle. 12(9),1433
  30. Kommoss S, Anglesio MS, Mackenzie R, Yang W, Senz J, Ho J, Bell L, Lee S, Lorette J, Huntsman DG, Blake Gilks C. (2013-01-25). FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines. Mod Pathol. 26(6),860
  31. Gurung A, Hung T, Morin J, Gilks CB. (2013-01-01). Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates. Histopathology. 62(1),59
  32. Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullum M, Gilks CB. (2013-01-01). Prophylactic Salpingectomy and Delayed Oophorectomy as an Alternative for BRCA Mutation Carriers. Obstet Gynecol. 121(1),14
  33. Beirne JP, Quinn JE, Maxwell P, Kalloger SE, McAlpine J, Gilks CB, Harley IJ, McCluggage WG. (2013-01-01). BRCA1 Immunohistochemical Staining as a Prognostic Indicator in Uterine Serous Carcinoma. Int J Gynecol Cancer. 23(1),113
  34. Hanna W, Barnes P, Berendt R, Chang M, Magliocco A, Mulligan AM, Rees H, Miller N, Elavathil L, Gilks B, Pettigrew N, Pilavdzic D, Sengupta S. (2012-12-01). Testing for her2 in breast cancer: current pathology challenges faced in Canada. Curr Oncol. 19(6),315
  35. D'Angelo E, Ali RH, Espinosa I, Lee CH, Huntsman DG, Gilks B, Prat J. (2012-12-01). Endometrial Stromal Sarcomas With Sex Cord Differentiation Are Associated With PHF1 Rearrangement. Am J Surg Pathol. 37(4),514
  36. Tone A, McAlpine J, Finlayson S, Gilks CB, Heywood M, Huntsman D, Miller D. (2012-12-01). It sounded like a good idea at the time. J Obstet Gynaecol Can. 34(12),1127
  37. Isphording A, Ali RH, Irving J, Goytain A, Nelnyk N, Hoang LN, Gilks CB, Huntsman DG, Nielsen TO, Nucci MR, Lee CH. (2012-11-15). YWHAE-FAM22 endometrial stromal sarcoma: diagnosis by reverse transcription-polymerase chain reaction in formalin-fixed, paraffin embedded tumor. Hum Pathol. 44(5),837
  38. Lim D, Wang WL, Lee CH, Dodge T, Gilks B, Oliva E. (2012-11-13). Old versus new FIGO staging systems in predicting overall survival in patients with uterine leiomyosarcoma: A study of 86 cases. Gynecol Oncol. 128(2),322
  39. Lu FI, Gilks CB, Mulligan AM, Ryan P, Allo G, Sy K, Shaw PA, Pollett A, Clarke BA. (2012-11-01). Prevalence of Loss of Expression of DNA Mismatch Repair Proteins in Primary Epithelial Ovarian Tumors. Int J Gynecol Pathol. 31(6),524
  40. Ali RH, Seidman JD, Luk M, Kalloger S, Gilks CB. (2012-11-01). Transitional Cell Carcinoma of the Ovary is Related to High-grade Serous Carcinoma and is Distinct From Malignant Brenner Tumor. Int J Gynecol Pathol. 31(6),199
  41. Chan A, Gilks B, Kwon J, Tinker AV. (2012-10-01). New insights into the pathogenesis of ovarian carcinoma: time to rethink ovarian cancer screening. Obstet Gynecol. 120(4),935
  42. Mohammad T, Garratt J, Torlakovic E, Gilks B, Churg A. (2012-10-01). Utility of a CEA, CD15, calretinin, and CK5/6 panel for distinguishing between mesotheliomas and pulmonary adenocarcinomas in clinical practice. Am J Surg Pathol. 36(10),1503
  43. Lee CH, Ali RH, Rouzbahman M, Marino-Enriquez A, Zhu M, Guo X, Brunner AL, Chiang S, Leung S, Nelnyk N, Huntsman DG, Blake Gilks C, Nielsen TO, Dal Cin P, van de Rijn M, Oliva E, Fletcher JA, Nucci MR. (2012-10-01). Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement. Am J Surg Pathol. 36(10),1562
  44. Spowart JE, Townsend KN, Huwait H, Eshragh S, West NR, Ries JN, Kalloger S, Anglesio M, Gorski SM, Watson PH, Gilks CB, Huntsman DG, Lum JJ. (2012-08-27). The Autophagy Protein LC3A Correlates with Hypoxia and is a Prognostic Marker of Patient Survival in Clear Cell Ovarian Cancer. J Pathol. 228(4),437
  45. Anglesio M, Kommoss S, Tolcher M, Clarke B, Galletta L, Porter H, Damaraju S, Fereday S, Winterhoff B, Kalloger S, Senz J, Yang W, Steed H, Allo G, Ferguson S, Shaw P, Teoman A, Garcia J, Schoolmeester J, Bakkum-Gamez J, Tinker A, Bowtell D, Huntsman D, Gilks C, McAlpine J. (2012-08-16). Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol. 229(1),111
  46. Schrader KA, Hurlburt J, Kalloger SE, Hansford S, Young S, Huntsman DG, Gilks CB, McAlpine JN. (2012-08-01). Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. Obstet Gynecol. 120(2),235
  47. Oishi H, Klausen C, Bentley GE, Osugi T, Tsutsui K, Gilks CB, Yano T, Leung PC. (2012-07-01). The Human Gonadotropin-Inhibitory Hormone Ortholog RFamide-Related Peptide-3 Suppresses Gonadotropin-Induced Progesterone Production in Human Granulosa Cells. Endocrinology. 153(7),3435
  48. McConechy MK, Ding J, Cheang MC, Wiegand KC, Senz J, Tone AA, Yang W, Prentice LM, Tse K, Zeng T, McDonald H, Schmidt AP, Mutch DG, McAlpine JN, Hirst M, Shah SP, Lee CH, Goodfellow PJ, Gilks CB, Huntsman DG. (2012-05-31). Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol. 228(1),20
  49. Won JR, Gao D, Grant D, Cupples J, Rahemtulla A, Wolber R, Nielsen TO, Gilks CB. (2012-05-29). Variable performance of commercial epidermal growth factor receptor antibodies in detection of basal-like breast cancer. Histopathology. 61(3),518
  50. Tone AA, Salvador S, Finlayson SJ, Tinker AV, Kwon JS, Lee CH, Cohen T, Ehlen T, Lee M, Carey MS, Heywood M, Pike J, Hoskins PJ, Stuart GC, Swenerton KD, Huntsman DG, Gilks CB, Miller DM, McAlpine JN. (2012-05-01). The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol. 10(5),296
  51. Hoskins PJ, Le N, Gilks B, Tinker A, Santos J, Wong F, Swenerton KD. (2012-04-09). Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation. J Clin Oncol. 30(14),1656
  52. Lee CH, Mariño-Enriquez A, Ou W, Zhu M, Ali RH, Chiang S, Amant F, Gilks CB, van de Rijn M, Oliva E, Debiec-Rychter M, Cin PD, Fletcher JA, Nucci MR. (2012-03-27). The Clinicopathologic Features of YWHAE-FAM22 Endometrial Stromal Sarcomas: A Histologically High-grade and Clinically Aggressive Tumor. Am J Surg Pathol. 36(5),641
  53. Chiu CG, Chan SK, Fang ZA, Masoudi H, Wood-Baker R, Jones SJ, Gilks B, Laskin J, Wiseman SM. (2012-03-06). Beta-catenin expression is prognostic of improved non-small cell lung cancer survival. Am J Surg. 203(5),654
  54. Cipollone JA, Graves ML, Köbel M, Kalloger SE, Poon T, Gilks CB, McNagny KM, Roskelley CD. (2012-03-01). The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma. Clin Exp Metastasis. 29(3),239
  55. McCluggage WG, Connolly LE, McBride HA, Kalloger S, Gilks CB. (2012-03-01). HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis. Histopathology. 60(4),547
  56. Milne K, Alexander C, Webb JR, Sun W, Dillon K, Kalloger SE, Gilks CB, Clarke B, Köbel M, Nelson BH. (2012-02-27). Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. J Transl Med. 10(1),33
  57. Yerushalmi R, Gelmon KA, Leung S, Gao D, Cheang M, Pollak M, Turashvili G, Gilks BC, Kennecke H. (2012-02-01). Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. Breast Cancer Res Treat. 132(1),131
  58. Ryan P, Mulligan AM, Aronson M, Ferguson SE, Bapat B, Semotiuk K, Holter S, Kwon J, Kalloger SE, Gilks CB, Gallinger S, Pollett A, Clarke BA. (2012-02-01). Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. Cancer. 118(3),681
  59. McAlpine JN, Porter H, Köbel M, Nelson BH, Prentice LM, Kalloger SE, Senz J, Milne K, Ding J, Shah SP, Huntsman DG, Gilks CB. (2012-01-27). BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol. 25(5),740
  60. Heravi-Moussavi A, Anglesio MS, Cheng SW, Senz J, Yang W, Prentice L, Fejes AP, Chow C, Tone A, Kalloger SE, Hamel N, Roth A, Ha G, Wan AN, Maines-Bandiera S, Salamanca C, Pasini B, Clarke BA, Lee AF, Lee CH, Zhao C, Young RH, Aparicio SA, Sorensen PH, Woo MM, Boyd N, Jones SJ, Hirst M, Marra MA, Gilks B, Shah SP, Foulkes WD, Morin GB, Huntsman DG. (2012-01-19). Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med. 366(3),234
  61. Lee CH, Ou WB, Mariño-Enriquez A, Zhu M, Mayeda M, Wang Y, Guo X, Brunner AL, Amant F, French CA, West RB, McAlpine JN, Gilks CB, Yaffe MB, Prentice LM, McPherson A, Jones SJ, Marra MA, Shah SP, van de Rijn M, Huntsman DG, Dal Cin P, Debiec-Rychter M, Nucci MR, Fletcher JA. (2012-01-17). 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci U S A. 109(3),929
  62. Hunter SM, Anglesio MS, Sharma R, Gilks B, Melnyk N, Chiew YE, Longacre TA, Defazio A, Huntsman DG, Gorringe KL, Campbell IG. (2011-12-01). Copy number aberrations in benign serous ovarian tumors: a case for reclassification? Clin Cancer Res. 17(23),7273
  63. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A. (2011-09-01). Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 12(9),852
  64. Gilks CB, Clarke BA, Han G, Köbel M, Longacre T, McCluggage WG, Seidman JD, Shaw P, Soslow RA. (2011-09-01). Letter to the editor regarding 'Roh MH, Lassin Y, Miron A et al. High-grade fimbrial-ovarian carcinomas are unified by p53, PTEN and PAX2 expression'. Mod Pathol. 24(9),1281
  65. Chiang S, Ali R, Melnyk N, McAlpine JN, Huntsman DG, Gilks CB, Lee CH, Oliva E. (2011-09-01). Frequency of known gene rearrangements in endometrial stromal tumors. Am J Surg Pathol. 35(9),1364
  66. McCluggage WG, Soslow RA, Gilks CB. (2011-08-22). Patterns of p53 immunoreactivity in endometrial carcinomas: 'all or nothing' staining is of importance. Histopathology. 59(4),786
  67. Espinosa I, Edris B, Lee CH, Wei Cheng H, Gilks CB, Wang Y, Montgomery KD, Varma S, Li R, Marinelli RJ, West RB, Nielsen T, Beck AH, van de Rijn M. (2011-08-18). CSF1 Expression in Nongynecological Leiomyosarcoma Is Associated with Increased Tumor Angiogenesis. Am J Pathol. 179(4),2100
  68. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L, Coukos G. (2011-07-13). Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 475(7355),226
  69. Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D, Gout PW, Miller DM, Gilks CB, Huntsman DG, Ellard SL, Wang YZ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Birrer MJ. (2011-07-06). Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One. 6(7),21121
  70. Alhejaily A, Wood B, Foster CJ, Farmer PL, Gilks CB, Brettschneider J, Day AG, Feilotter HE, Baetz T, Lebrun DP. (2011-07-01). Differential expression of cell-cycle regulatory proteins defines distinct classes of follicular lymphoma. Hum Pathol. 42(7),972
  71. Köbel M, Turbin D, Kalloger SE, Gao D, Huntsman DG, Gilks CB. (2011-07-01). Biomarker Expression in Pelvic High-grade Serous Carcinoma: Comparison of Ovarian and Omental Sites. Int J Gynecol Pathol. 30(4),366
  72. Wiegand KC, Lee AF, Al-Agha OM, Chow C, Kalloger SE, Scott DW, Steidl C, Wiseman SM, Gascoyne RD, Gilks B, Huntsman DG. (2011-07-01). Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol. 224(3),328
  73. Makretsov N, Gilks CB, Alaghehbandan R, Garratt J, Quenneville L, Mercer J, Palavdzic D, Torlakovic EE. (2011-07-01). Development of an evidence-based approach to external quality assurance for breast cancer hormone receptor immunohistochemistry: comparison of reference values. Arch Pathol Lab Med. 135(7),874
  74. Cheung CC, Neufeld H, Lining LA, Pilavdzic D, Copete M, Garratt J, Gilks B, Torlakovic EE. (2011-07-01). The Laboratory Score/Reference Method Score Ratio (LSRSR) Is a Novel Tool for Monitoring Laboratory Performance in Immunohistochemistry Proficiency Testing of Hormone Receptors in Breast Cancer: The CIQC Experience. Am J Clin Pathol. 136(1),67
  75. Kwon JS, Scott JL, Gilks CB, Daniels MS, Sun CC, Lu KH. (2011-05-02). Testing Women With Endometrial Cancer to Detect Lynch Syndrome. J Clin Oncol. 29(16),2247
  76. Al-Barrak J, Santos JL, Tinker A, Hoskins P, Gilks CB, Lau H, Swenerton KD. (2011-04-03). Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma. Gynecol Oncol. 122(1),107
  77. Al-Agha OM, Huwait HF, Chow C, Yang W, Senz J, Kalloger SE, Huntsman DG, Young RH, Gilks CB. (2011-04-01). FOXL2 Is a Sensitive and Specific Marker for Sex Cord-Stromal Tumors of the Ovary. Am J Surg Pathol. 35(4),484
  78. McConechy MK, Anglesio MS, Kalloger SE, Yang W, Senz J, Chow C, Heravi-Moussavi A, Morin GB, Mes-Masson AM; Australian Ovarian Cancer Study Group, Carey MS, McAlpine JN, Kwon JS, Prentice LM, Boyd N, Shah SP, Gilks CB, Huntsman DG. (2011-03-07). Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol. 223(5),567
  79. Anglesio MS, George J, Kulbe H, Friedlander ML, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, Chakravarty P, Gorringe KL, Campbell IG, Group AO, Okamoto A, Birrer MJ, Huntsman DG, Defazio A, Kalloger SE, Balkwill FR, Gilks B, Bowtell DD. (2011-02-22). IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer. Clin Cancer Res. 17(8),2538
  80. Boylan KL, Misemer B, Derycke MS, Andersen JD, Harrington KM, Kalloger SE, Gilks CB, Pambuccian SE, Skubitz AP. (2011-02-22). Claudin 4 Is Differentially Expressed between Ovarian Cancer Subtypes and Plays a Role in Spheroid Formation. Int J Mol Sci. 12(2),1334
  81. D'Angelo E, Espinosa I, Ali R, Gilks CB, Rijn MV, Lee CH, Prat J. (2011-02-12). Uterine leiomyosarcomas: Tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis. Gynecol Oncol. 121(2),328
  82. Copete M, Garratt J, Gilks B, Pilavdzic D, Richard B, Bigras G, Mitchell S, Lining LA, Cheung C, Torlakovic EE. (2011-01-22). Inappropriate calibration and optimisation of pan-keratin (pan-CK) and low molecular weight keratin (LMWCK) immunohistochemistry tests: Canadian Immunohistochemistry Quality Control (CIQC) experience. J Clin Pathol. 64(3),220
  83. McAlpine JN, El Hallani S, Lam SF, Kalloger SE, Luk M, Huntsman DG, Macaulay C, Gilks CB, Miller DM, Lane PM. (2011-01-14). Autofluorescence imaging can identify preinvasive or clinically occult lesions in fallopian tube epithelium: A promising step towards screening and early detection. Gynecol Oncol. 120(3),385
  84. DeLair D, Oliva E, Köbel M, Macias A, Gilks CB, Soslow RA. (2011-01-01). Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. Am J Surg Pathol. 35(1),36
  85. Kalloger SE, Köbel M, Leung S, Mehl E, Gao D, Marcon KM, Chow C, Clarke BA, Huntsman DG, Gilks CB. (2010-12-03). Calculator for ovarian carcinoma subtype prediction. Mod Pathol. 24(4),512
  86. Hung T, Wolber R, Garratt J, Kalloger S, Gilks CB. (2010-12-01). Improved breast cancer biomarker detection through a simple, high frequency, low cost external proficiency testing program. Pathology. 42(7),637
  87. Kortmann UK, McAlpine JN, Xue H, Guan J, Ha G, Tully S, Shafait S, Lau A, Cranston A, O'Connor MJ, Huntsman DG, Wang Y, Gilks B. (2010-11-19). Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin Cancer Res. 17(4),783
  88. Ota T, Clayton AC, Minot DM, Shridhar V, Hartmann LC, Gilks CB, Chien JR. (2010-11-12). Minichromosome maintenance protein 7 as a potential prognostic factor for progression-free survival in high-grade serous carcinomas of the ovary. Mod Pathol. 24(2),277
  89. Derycke MS, Pambuccian SE, Gilks CB, Kalloger SE, Ghidouche A, Lopez M, Bliss RL, Geller MA, Argenta PA, Harrington KM, Skubitz AP. (2010-11-01). Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker. Am J Clin Pathol. 134(5),835
  90. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih IeM, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG. (2010-10-14). ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 363(16),1532
  91. Pradhan M, Risberg BA, Tropé CG, van de Rijn M, Gilks CB, Lee CH. (2010-09-15). Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation. BMC Cancer. 10(0),493
  92. Swenerton KD, Santos JL, Gilks CB, Köbel M, Hoskins PJ, Wong F, Le ND. (2010-08-06). Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers. Ann Oncol. 22(2),341
  93. Mulligan AM, Plotkin A, Rouzbahman M, Soslow RA, Gilks CB, Clarke BA. (2010-08-01). Endometrial Giant Cell Carcinoma: A Case Series and Review of the Spectrum of Endometrial Neoplasms Containing Giant Cells. Am J Surg Pathol. 34(8),1132
  94. Meyer SE, Hasenstein JR, Baktula A, Velu CS, Xu Y, Wan H, Whitsett JA, Gilks CB, Grimes HL. (2010-07-16). Kruppel-Like Factor 5 Is Not Required for K-RasG12D Lung Tumorigenesis, but Represses ABCG2 Expression and Is Associated with Better Disease-Specific Survival. Am J Pathol. 177(3),1503
  95. Köbel M, Reuss A, Bois AD, Kommoss S, Kommoss F, Gao D, Kalloger SE, Huntsman DG, Gilks CB. (2010-07-13). The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol. 222(2),191
  96. Gilks CB, Huntsman DG. (2010-07-01). Diagnostic Uncertainty in the Interpretation of Small Atypical Acinar Lesions of Prostate. Am J Surg Pathol. 34(7),1071
  97. Alkushi A, Köbel M, Kalloger SE, Gilks CB. (2010-07-01). High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int J Gynecol Pathol. 29(4),343
  98. Köbel M, Kalloger SE, Baker PM, Ewanowich CA, Arseneau J, Zherebitskiy V, Abdulkarim S, Leung S, Duggan MA, Fontaine D, Parker R, Huntsman DG, Gilks CB. (2010-07-01). Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study. Am J Surg Pathol. 34(7),984
  99. Chiu CG, Masoudi H, Leung S, Voduc DK, Gilks B, Huntsman DG, Wiseman SM. (2010-06-01). HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients. Ann Surg. 251(6),1107
  100. Carey MS, Agarwal R, Gilks B, Swenerton K, Kalloger S, Santos J, Ju Z, Lu Y, Zhang F, Coombes KR, Miller D, Huntsman D, Mills GB, Hennessy BT. (2010-05-15). Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res. 16(10),2852
  101. Köbel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, Gilks CB. (2010-05-01). Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 29(3),203
  102. Clarke BA, Gilks CB. (2010-05-01). Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type. J Clin Pathol. 63(5),410
  103. Torlakovic EE, Riddell R, Banerjee D, El-Zimaity H, Pilavdzic D, Dawe P, Magliocco A, Barnes P, Berendt R, Cook D, Gilks B, Williams G, Perez-Ordonez B, Wehrli B, Swanson PE, Otis CN, Nielsen S, Vyberg M, Butany J. (2010-03-01). Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests. Am J Clin Pathol. 133(3),354
  104. Tabrizi AD, Kalloger SE, Köbel M, Cipollone J, Roskelley CD, Mehl E, Gilks CB. (2010-03-01). Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases. Int J Gynecol Pathol. 29(2),99
  105. Maines-Bandiera S, Woo MM, Borugian M, Molday LL, Hii T, Gilks B, Leung PC, Molday RS, Auersperg N. (2010-01-01). Oviductal glycoprotein (OVGP1, MUC9): a differentiation-based mucin present in serum of women with ovarian cancer. Int J Gynecol Cancer. 20(1),16
  106. Gilks CB. (2009-12-30). Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma. J Oncol. 2010(0),0
  107. Köbel M, Gilks CB, Huntsman DG. (2009-12-15). Adult-type granulosa cell tumors and FOXL2 mutation. Cancer Res. 69(24),9160
  108. McAlpine JN, Wiegand KC, Vang R, Ronnett BM, Adamiak A, Köbel M, Kalloger SE, Swenerton KD, Huntsman DG, Gilks CB, Miller DM. (2009-12-10). HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer. 9(0),433
  109. Schrader KA, Gorbatcheva B, Senz J, Heravi-Moussavi A, Melnyk N, Salamanca C, Maines-Bandiera S, Cooke SL, Leung P, Brenton JD, Gilks CB, Monahan J, Huntsman DG. (2009-11-24). The Specificity of the FOXL2 c.402C>G Somatic Mutation: A Survey of Solid Tumors. PLoS One. 4(11),7988
  110. Watson PH, Wilson-McManus JE, Barnes RO, Giesz SC, Png A, Hegele RG, Brinkman JN, Mackenzie IR, Huntsman DG, Junker A, Gilks B, Skarsgard E, Burgess M, Aparicio S, McManus BM. (2009-11-12). Evolutionary concepts in biobanking - the BC BioLibrary. J Transl Med. 7(0),95
  111. Jensen KC, Nielsen TO, Gilks CB, West RB. (2009-11-01). HER2 Intermediate Breast Cancers. Am J Surg Pathol. 33(11),1739
  112. KŲbel M, Kalloger SE, Santos JL, Huntsman DG, Gilks CB, Swenerton KD. (2009-10-10). Tumor type and substage predict survival in stage I and II ovarian carcinoma: Insights and implications. Gynecol Oncol. 116(1),50
  113. Lee CH, Subramanian S, Beck AH, Espinosa I, Senz J, Zhu SX, Huntsman D, van de Rijn M, Gilks CB. (2009-10-02). MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. PLoS One. 4(10),7314
  114. Lee CH, Turbin DA, Sung YC, Espinosa I, Montgomery K, van de Rijn M, Gilks CB. (2009-09-04). A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors. Mod Pathol. 22(12),1519
  115. Milne K, KŲbel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH, Nelson BH. (2009-07-29). Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One. 4(7),6412
  116. Gilks CB, Prat J. (2009-06-24). Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol. 40(9),1213
  117. Shah SP, Koebel M, Senz J, Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A, Mehl E, Kalloger SE, Sun M, Giuliany R, Yorida E, Jones S, Varhol R, Swenerton KD, Miller D, Clement PB, Crane C, Madore J, Provencher D, Leung P, DeFazio A, Khattra J, Turashvili G, Zhao Y, Zeng T, Glover JN, Vanderhyden B, Zhao C, Parkinson CA, Jimenez-Linan M, Bowtell DD, Mes-Masson AM, Brenton JD, Aparicio SA, Boyd N, Hirst M, Gilks CB, Marra M, Huntsman DG. (2009-06-10). Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med. 360(26),2719
  118. Liu P, Khurana A, Rattan R, He X, Kalloger S, Dowdy S, Gilks B, Shridhar V. (2009-06-01). Regulation of HSulf-1 expression by variant hepatic nuclear factor 1 in ovarian cancer. Cancer Res. 69(11),4843
  119. Turashvili G, Leung S, Turbin D, Montgomery K, Gilks B, West R, Carrier M, Huntsman D, Aparicio S. (2009-05-29). Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis. BMC Cancer. 9(0),165
  120. Espinosa I, Beck AH, Lee CH, Zhu S, Montgomery KD, Marinelli RJ, Ganjoo KN, Nielsen TO, Gilks CB, West RB, van de Rijn M. (2009-05-14). Coordinate Expression of Colony-Stimulating Factor-1 and Colony-Stimulating Factor-1-Related Proteins Is Associated with Poor Prognosis in Gynecological and Nongynecological Leiomyosarcoma. Am J Pathol. 174(6),2347
  121. Terry J, Torlakovic EE, Garratt J, Miller D, K√∂bel M, Cooper J, Bahzad S, Pilavdzic D, O ľmalley F, O ľbrien AE, Sengupta S, Alport E, T√™tu B, Knight B, Pettigrew NM, Berendt R, Wolber R, Trotter MJ, Riddell RH, Gaboury L, Elms F, Magliocco A, Barnes P, Gown AM, Gilks CB. (2009-04-09). Implementation of a Canadian External Quality Assurance Program for Breast Cancer Biomarkers: An Initiative of Canadian Quality Control in Immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/Immunohistochemistry. Appl Immunohistochem Mol Morphol. 17(5),375
  122. Köbel M, Gilks CB, Huntsman DG. (2009-03-12). Dicer and Drosha in ovarian cancer. N Engl J Med. 360(11),1150
  123. Renouf DJ, Wood-Baker R, Ionescu DN, Leung S, Masoudi H, Gilks CB, Laskin J. (2009-02-23). BCL-2 Expression is Prognostic for Improved Survival in Non-small Cell Lung Cancer. J Thorac Oncol. 4(4),486
  124. Salvador S, Gilks B, Köbel M, Huntsman D, Rosen B, Miller D. (2009-02-01). The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer. 19(1),58
  125. Köbel M, Xu H, Bourne PA, Spaulding BO, Shih IM, Mao TL, Soslow RA, Ewanowich CA, Kalloger SE, Mehl E, Lee CH, Huntsman D, Gilks CB. (2009-01-09). IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod Pathol. 22(3),469
  126. Köbel M, Kalloger SE, Carrick J, Huntsman D, Asad H, Oliva E, Ewanowich CA, Soslow RA, Gilks CB. (2009-01-01). A Limited Panel of Immunomarkers Can Reliably Distinguish Between Clear Cell and High-grade Serous Carcinoma of the Ovary. Am J Surg Pathol. 33(1),14
  127. Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, Turbin D, Kalloger S, Han G, Ceballos K, Cadungog MG, Huntsman DG, Coukos G, Gilks CB. (2008-12-05). Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol. 22(3),393
  128. Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D. (2008-12-02). Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 5(12),232
  129. Ronnett BM, Yemelyanova AV, Vang R, Gilks CB, Miller D, Gravitt PE, Kurman RJ. (2008-12-01). Endocervical Adenocarcinomas With Ovarian Metastases: Analysis of 29 Cases With Emphasis on Minimally Invasive Cervical Tumors and the Ability of the Metastases to Simulate Primary Ovarian Neoplasms. Am J Surg Pathol. 32(12),1835
  130. Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM, Huntsman D, Olivotto IA, Nielsen TO, Gelmon K. (2008-11-10). Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers. J Clin Oncol. 26(35),5697
  131. Milne K, Barnes RO, Girardin A, Mawer MA, Nesslinger NJ, Ng A, Nielsen JS, Sahota R, Tran E, Webb JR, Wong MQ, Wick DA, Wray A, McMurtrie E, Köbel M, Kalloger SE, Gilks CB, Watson PH, Nelson BH. (2008-10-15). Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. PLoS ONE. 3(10),3409
  132. Wong MP, Cheang M, Yorida E, Coldman A, Gilks CB, Huntsman D, Berean K. (2008-10-01). Loss of desmoglein 1 expression associated with worse prognosis in head and neck squamous cell carcinoma patients. Pathology. 40(6),611
  133. Jensen KC, Schaeffer DF, Cheang M, Montgomery K, West RB, Gilks CB, Ross D, Turashvili G, Schnitt S, van de Rijn M. (2008-09-26). Characterization of a novel anti-fatty acid synthase (FASN) antiserum in breast tissue. Mod Pathol. 21(12),1413
  134. Salvador S, Rempel A, Soslow RA, Gilks B, Huntsman D, Miller D. (2008-09-01). Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol Oncol. 110(3),408
  135. Woo MM, Salamanca CM, Symowicz J, Stack MS, Miller DM, Leung PC, Gilks CB, Auersperg N. (2008-08-03). SV40 early genes induce neoplastic properties in serous borderline ovarian tumor cells. Gynecol Oncol. 111(1),125
  136. Köbel M, Huntsman D, Gilks CB. (2008-08-01). Critical molecular abnormalities in high-grade serous carcinoma of the ovary. Expert Rev Mol Med. 22(0),10
  137. Gilks CB, Ionescu DN, Kalloger SE, Köbel M, Irving J, Clarke B, Santos J, Le N, Moravan V, Swenerton K; Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency. (2008-08-01). Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol. 39(8),1239
  138. Auersperg N, Woo MM, Gilks CB. (2008-07-07). The origin of ovarian carcinomas: A developmental view. Gynecol Oncol. 110(3),452
  139. Han G, Gilks CB, Leung S, Ewanowich CA, Irving JA, Longacre TA, Soslow RA. (2008-07-01). Mixed Ovarian Epithelial Carcinomas With Clear Cell and Serous Components are Variants of High-grade Serous Carcinoma: An Interobserver Correlative and Immunohistochemical Study of 32 Cases. Am J Surg Pathol. 32(7),955
  140. Press JZ, Kenyon JA, Xue H, Miller MA, De Luca A, Miller DM, Huntsman DG, Gilks CB, McAlpine JN, Wang YZ. (2008-06-10). Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. Gynecol Oncol. 110(2),256
  141. Brown LA, Kalloger SE, Miller MA, Shih IeM, McKinney SE, Santos JL, Swenerton K, Spellman PT, Gray J, Gilks CB, Huntsman DG. (2008-06-01). Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes Cancer. 47(6),481
  142. Turashvili G, Hayes M, Gilks B, Watson P, Aparicio S. (2008-04-24). Are columnar cell lesions the earliest histologically detectable non-obligate precursor of breast cancer? Virchows Arch. 452(6),589
  143. Beck AH, Espinosa I, Gilks CB, van de Rijn M, West RB. (2008-04-14). The fibromatosis signature defines a robust stromal response in breast carcinoma. Lab Invest. 88(6),591
  144. Lee CH, Espinosa I, Vrijaldenhoven S, Subramanian S, Montgomery KD, Zhu S, Marinelli RJ, Peterse JL, Poulin N, Nielsen TO, West RB, Gilks CB, van de Rijn M. (2008-03-01). Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res. 14(5),1423
  145. Woo MM, Salamanca CM, Miller M, Symowicz J, Leung PC, Oliveira C, Ehlen TG, Gilks CB, Huntsman D, Auersperg N. (2008-01-23). Serous borderline ovarian tumors in long-term culture: phenotypic and genotypic distinction from invasive ovarian carcinomas. Int J Gynecol Cancer. 18(6),1234
  146. Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, Kaurah P, Kalloger SE, Blood KA, Smith M, Spellman PT, Wang Y, Miller DM, Horsman D, Faham M, Gilks CB, Gray J, Huntsman DG. (2008-01-22). Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer. 8(17),0
  147. Jensen KC, Turbin DA, Leung S, Miller MA, Johnson K, Norris B, Hastie T, McKinney S, Nielsen TO, Huntsman DG, Gilks CB, West RB. (2008-01-09). New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up. Breast Cancer Res Treat. 112(3),453
  148. Prentice LM, Klausen C, Kalloger S, Kobel M, McKinney S, Santos JL, Kenney C, Mehl E, Gilks CB, Leung P, Swenerton K, Huntsman DG, Aparicio SA. (2007-11-15). Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. BMC Med. 5(1),33
  149. Turbin DA, Leung S, Cheang MC, Kennecke HA, Montgomery KD, McKinney S, Treaba DO, Boyd N, Goldstein LC, Badve S, Gown AM, van de Rijn M, Nielsen TO, Gilks CB, Huntsman DG. (2007-10-03). Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. Breast Cancer Res Treat. 110(3),417
  150. Ota T, Gilks CB, Longacre T, Leung PC, Auersperg N. (2007-09-01). HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features. Reprod Sci. 14(6),605
  151. Alkushi A, Clarke BA, Akbari M, Makretsov N, Lim P, Miller D, Magliocco A, Coldman A, van de Rijn M, Huntsman D, Parker R, Gilks CB. (2007-08-24). Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. Mod Pathol. 20(11),1156
  152. Wiseman SM, Griffith OL, Deen S, Rajput A, Masoudi H, Gilks B, Goldstein L, Gown A, Jones SJ. (2007-08-01). Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch Surg. 142(8),717
  153. Cupp JS, Miller MA, Montgomery KD, Nielsen TO, Oʼconnell JX, Huntsman D, Rijn MV, Gilks CB, West RB. (2007-06-01). Translocation and Expression of CSF1 in Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor, Rheumatoid Arthritis and Other Reactive Synovitides. Am J Surg Pathol. 31(6),970
  154. Rajput AB, Turbin DA, Cheang MC, Voduc DK, Leung S, Gelmon KA, Gilks CB, Huntsman DG. (2007-03-13). Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Res Treat. 107(2),249
  155. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Bugis S, Filipenko D, Huntsman D, Gilks B. (2007-02-01). Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol. 14(2),719
  156. Ionescu DN, Treaba D, Gilks CB, Leung S, Renouf D, Laskin J, Wood-Baker R, Gown AM. (2007-01-01). Nonsmall Cell Lung Carcinoma With Neuroendocrine Differentiation-An Entity of No Clinical or Prognostic Significance. Am J Surg Pathol. 31(1),26
  157. Cheang MC, Treaba DO, Speers CH, Olivotto IA, Bajdik CD, Chia SK, Goldstein LC, Gelmon KA, Huntsman D, Gilks CB, Nielsen TO, Gown AM. (2006-12-20). Immunohistochemical Detection Using the New Rabbit Monoclonal Antibody SP1 of Estrogen Receptor in Breast Cancer Is Superior to Mouse Monoclonal Antibody 1D5 in Predicting Survival. J Clin Oncol. 24(36),5637
  158. Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG. (2006-11-24). Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Mod Pathol. 20(1),84
  159. Hayes DN, Monti S, Parmigiani G, Gilks CB, Naoki K, Bhattacharjee A, Socinski MA, Perou C, Meyerson M. (2006-11-01). Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol. 24(31),5079
  160. Masoudi H, Van Niekerk DJ, Gilks CB, Cheang M, Bilek K, Fischer U, Ehlen T, Miller D, Horn LC. (2006-11-01). Loss of p16 INK4 expression in invasive squamous cell carcinoma of the uterine cervix is an adverse prognostic marker. Histopathology 49(5),542
  161. Choi JH, Gilks CB, Auersperg N, Leung PC. (2006-09-05). Immunolocalization of Gonadotropin-Releasing Hormone (GnRH)-I, GnRH-II, and Type-I GnRH Receptor during Follicular Development in the Human Ovary. J Clin Endocrinol Metab. 91(11),4562
  162. Mao TL, Hsu CY, Yen MJ, Gilks B, Sheu JJ, Gabrielson E, Vang R, Cope L, Kurman RJ, Wang TL, Shih IeM. (2006-09-01). Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma Hum Pathol. 37(9),1169
  163. Tse GM, Tan PH, Lui PC, Gilks B, Poon CS, Ma TK, Law BK, Lam WW. (2006-05-12). The role of immunohistochemistry for smooth muscle actin, p63, CD10 and CK 14 in the differential diagnosis of papillary lesions of the breast. J Clin Pathol. 60(3),315
  164. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Filipenko D, Huntsman D, Gilks B. (2006-05-01). Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am J Surg. 191(5),581
  165. Wu J, Lee C, Yokom D, Jiang H, Cheang MC, Yorida E, Turbin D, Berquin IM, Mertens PR, Iftner T, Gilks CB, Dunn SE. (2006-05-01). Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res. 66(9),4872
  166. Ota T, Choi KB, Gilks CB, Leung PC, Auersperg N. (2006-02-01). Cell type- and stage-specific changes in HOXA7 protein expression in human ovarian folliculogenesis: possible role of GDF-9. Differentiation. 74(1),1
  167. West RB, Rubin BP, Miller MA, Subramanian S, Kaygusuz G, Montgomery K, Zhu S, Marinelli RJ, De Luca A, Downs-Kelly E, Goldblum JR, Corless CL, Brown PO, Gilks CB, Nielsen TO, Huntsman D, van de Rijn M. (2006-01-17). A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A 103(3),690
  168. Turbin DA, Cheang MC, Bajdik CD, Gelmon KA, Yorida E, De Luca A, Nielsen TO, Huntsman DG, Gilks CB. (2006-01-01). MDM2 protein expression is a negative prognostic marker in breast carcinoma. Modern Pathology 19(1),69
  169. Tse GM, Tan PH, Ma TK, Gilks CB, Poon CS, Law BK. (2005-11-01). CD44s is useful in the differentiation of benign and malignant papillary lesions of the breast. J Clin Pathol. 58(11),1185
  170. Wang Y, Xue H, Cutz JC, Bayani J, Mawji NR, Chen WG, Goetz LJ, Hayward SW, Sadar MD, Gilks CB, Gout PW, Squire JA, Cunha GR, Wang YZ. (2005-11-01). An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest. 85(11),1392
  171. Brown LA, Irving J, Parker R, Kim H, Press JZ, Longacre TA, Chia S, Magliocco A, Makretsov N, Gilks B, Pollack J, Huntsman D. (2005-10-19). Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecologic Oncology 100(2),264
  172. Kucab JE, Lee C, Chen CS, Zhu J, Gilks CB, Cheang M, Huntsman D, Yorida E, Emerman J, Pollak M, Dunn SE. (2005-08-01). Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res. 7(5),796
  173. Martin JD, Gilks B, Lim P. (2005-08-01). Papillary serous carcinoma--a less radio-sensitive subtype of endometrial cancer. Gynecol Oncol. 98(2),299
  174. Prentice LM, Shadeo A, Lestou VS, Miller MA, Deleeuw RJ, Makretsov N, Turbin D, Brown LA, Macpherson N, Yorida E, Cheang MC, Bentley J, Chia S, Nielsen TO, Gilks CB, Lam W, Huntsman DG. (2005-07-18). NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis. Oncogene. 24(49),7281
  175. Ludwick C, Gilks CB, Miller D, Yaziji H, Clement PB. (2005-07-01). Aggressive behavior of stage I ovarian mucinous tumors lacking extensive infiltrative invasion: a report of four cases and review of the literature. Int J Gynecol Pathol. 24(3),205
  176. Sutherland BW, Kucab J, Wu J, Lee C, Cheang MC, Yorida E, Turbin D, Dedhar S, Nelson C, Pollak M, Leighton Grimes H, Miller K, Badve S, Huntsman D, Blake-Gilks C, Chen M, Pallen CJ, Dunn SE. (2005-06-16). Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene. 24(26),4281
  177. Wiseman SM, Makretsov N, Nielsen TO, Gilks B, Yorida E, Cheang M, Turbin D, Gelmon K, Huntsman DG. (2005-05-01). Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer. 103(9),1770
  178. Lee CH, Huntsman DG, Cheang MC, Parker RL, Brown L, Hoskins P, Miller D, Gilks CB. (2005-04-01). Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int J Gynecol Pathol. 24(2),147
  179. Stone JE, Parker R, Gilks CB, Stanbridge EJ, Liao SY, Aquino-Parsons C. (2005-04-01). Intratumoral oxygenation of invasive squamous cell carcimoma of the vulva is not correlated with regional lymph node metastasis. Eur J Gynaecol Oncol. 26(1),31
  180. Gilks CB, Vanderhyden BC, Zhu S, van de Rijn M, Longacre TA. (2005-03-01). Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol. 96(3),684
  181. Alkushi A, Abdul-Rahman ZH, Lim P, Schulzer M, Coldman A, Kalloger SE, Miller D, Gilks CB. (2005-03-01). Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. Am J Surg Pathol. 29(3),295
  182. Elishaev E, Gilks CB, Miller D, Srodon M, Kurman RJ, Ronnett BM. (2005-03-01). Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. Am J Surg Pathol. 29(3),281
  183. Woo MM, Alkushi A, Verhage HG, Magliocco AM, Leung PC, Gilks CB, Auersperg N. (2004-12-01). Gain of OGP, an estrogen-regulated oviduct-specific glycoprotein, is associated with the development of endometrial hyperplasia and endometrial cancer. Clinical Cancer Research 10(23),7958
  184. Lee CH, Xue H, Sutcliffe M, Gout PW, Huntsman DG, Miller DM, Gilks CB, Wang YZ. (2004-10-28). Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncology 96(1),48
  185. Kazanjian A, Wallis D, Au N, Nigam R, Venken KJ, Cagle PT, Dickey BF, Bellen HJ, Gilks CB, Grimes HL. (2004-10-01). Growth Factor Independence-1 Is Expressed in Primary Human Neuroendocrine Lung Carcinomas and Mediates the Differentiation of Murine Pulmonary Neuroendocrine Cells Cancer Research 64(19),6874
  186. Au NHC, Gown A, Cheang M, Huntsman D, Yorida E, Elliott WM, Flint J, English J, Gilks CB, Grimes HL. (2004-09-01). p63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol 12(3),240
  187. Au NHC, Cheang M, Huntsman DG, Yorida E, Coldman A, Elliot WM, Bebb G, Flint J, English J, Gilks CB, Grimes HL. (2004-09-01). Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers J of Pathology (UK) 204(1),101
  188. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hernandez-Boussard T, Cowan D, Dressler L, Livasy C, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM. (2004-08-15). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clinical Cancer Research 10(16),5367
  189. Somasiri A, Nielsen J, Makretsov N, Prentice L, Gilks CB, Chia SK, Gelmon KA, Kershaw DB, Huntsman DG, McNagny KM, and Roskelley CD. (2004-08-01). Overexpression of the Anti-Adhesin Podocalyxin Is an Independent Predictor of Breast Cancer Progression Cancer Research 64(15),5068
  190. Makretsov N, Huntsman D, Nielsen T, Yorida E, Peacock M, Cheang M, Sandra E.Dunn, Hayes M, Matt van de Rijn, Bajdik C, and Gilks B. (2004-08-01). Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data Identifies Prognostically Significant Groups of Breast Cancer Clinical Cancer Research 10(18),6143
  191. Ronnett BM, Kajdacsy-Balla A, Gilks CB, Merino MJ, Silva E, Werness BA, Young RH. (2004-08-01). Mucinous borderline ovarian tumors: points of general agreement and persistent controversies regarding nomenclature, diagnostic criteria, and behavior. Hum Pathol. 35(8),949
  192. Parker RL, Clement PB, Chercover DJ, Sornarajah T, Gilks CB. (2004-07-01). Early recurrence of ovarian serous borderline tumor as high-grade carcinoma: a report of two cases. Int J Gynecol Pathol. 23(3),265
  193. Gilks CB. (2004-07-01). Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol. 23(3),200
  194. Dabiri SH, Huntsman DG, Makretsov N, Cheang M, Gilks CB, Bajdik C, Gelmon KA, Chia S, Hayes MM. (2004-06-15). The presence of stromal mast cells identifies a subset of invasive breast cancers with a favourable prognosis. Mod Pathol 17(6),690
  195. Doan LL, Porter SD, Duan Z, Flubacher MM, Montoya D, Tsichlis PN, Horwitz M, Gilks CB, Grimes HL. (2004-05-06). Targeted transcriptional repression of Gfi1 by GFI1 and GFI1B in lymphoid cells. Nucleic Acids Res. 32(8),2508
  196. Woo MM, Gilks CB, Verhage HG, Longacre TA, Leung PCK, Auersperg N. (2004-05-01). Oviductal glycoprotein, a new differentiation-based indicator present in early ovarian epithelial neoplasia and cortical inclusion cysts Gynecologic Oncology 93(2),315
  197. Alkushi A, Lim P, Coldman A, Huntsman D, Miller D, Gilks CB. (2004-04-01). Interpretation of p53 immunohistochemical staining in endometrial carcinoma: establishing a clinically relevant cut-off. Int J Gynecol Pathol 23(2),129
  198. van de Rijn M, Gilks CB. (2004-02-01). Applications of microarrays to histopathology. Histopathology 44(1),97
  199. Nielsen TO, Andrews HN, Cheang M, Kucab JE, Hsu FD, Ragaz J, Gilks CB,Makretsov N, Bajdik CD, Brookes C, Neckers LM, Evdokimova V, Huntsman DG, Dunn SE (2004-01-01). Expression of the Insulin-Like Growth Factor I Receptor and Urokinase Plasminogen Activator in Breast Cancer Is Associated with Poor Survival Cancer Research 64(1),286
  200. Linn SC, West RB, Pollack JR, Zhu S, Hernandez-Boussard T, Nielsen TO, Rubin BP, Patel R, Goldblum JR, Siegmund D, Botstein D, Brown PO, Gilks CB, and van de Rijn M. (2003-12-10). Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans. Am J Pathol 163(6),2383
  201. Hughes-Davies L, Huntsman D, Ruas M, Fuks F, Bye J, Chin S-F, Milner J, Brown LA, Hsu F, Gilks B, Nielsen T, Schulzer M, Chia S, Ragaz J, Cahn A, Linger L, Ozdag H, Cattaneo E, Jordanova ES, Yu DS, Vnkitaraman A, Ponder B, Doherty A, Aparicio S, (2003-11-26). EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 115(5),523
  202. Makretsov N, Gilks CB, Coldman AJ, Hayes M, and Huntsman D. (2003-10-15). Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. Hum Pathol 34(10),1001
  203. Nielsen TO, Hsu FD, O'Connell JX, Gilks CB, Sorensen PHB, Linn SC, West RB, Liu CL, Botstein D, Brown PO, van de Rijn M (2003-10-01). Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology American Journal of Pathology 163(4),1449
  204. Alkushi A, Irving J, Hsu F, Dupuis B, Liu CL, Rijn M, Gilks CB. (2003-03-01). Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch 442(3),271
  205. Gilks CB, Alkushi A, Yue JJ, Lanvin D, Ehlen TG, Miller DM. (2003-01-01). Advanced-stage serous borderline tumors of the ovary: a clinicopathological study of 49 cases. Int J Gynecol Pathol. 22(1),29
  206. Hsu FD, Nielsen TO, Alkushi A, Dupuis B, Huntsman D, Liu CL, van de Rijn M, Gilks CB. (2002-12-15). Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. Mod Pathol 15(12),1374
  207. Liu CL, Prapong W, Natkunam Y, Alizadeh A, Montgomery K, Gilks CB, and van de Rijn M. (2002-11-15). Software tools for high-throughput analysis and archiving of immunohisothemistry staining data obtained with tissue microarrays. Am J Pathol 161(5),1557
  208. Irving JA, Dupuis B, Wang L, Gilks CB. (2002-07-01). Cyclical expression of the DNA mismatch repair enzyme hMLH1 in normal endometrium Fertil Steril. 78(1),195
  209. Poon KS, Gilks CB, Masterson JS. (2002-06-01). Metastatic Crohn's disease involving the genitalia. J Urol. 167(6),2541
  210. Al Kushi A, Lim P, Aquino-Parsons C, Gilks CB. (2002-04-05). Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium. Mod Pathol 15(4),365
  211. Parker RL, Huntsman DG, Lesack DW, Cupples JB, Grant DR, Akbari M, and Gilks CB. (2002-03-01). Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol. 117(0),723
  212. Al-Ghamdi A, Freedman D, Miller D, Poh C, Rosin M, Zhang L, Gilks CB. (2002-01-01). Vulvar squamous cell carcinoma in young women: a clinicopathologic study of 21 cases. Gynecol Oncol. 84(1),94

(b) Chapters

Invited contributor to Pathology and Genetics of Tumors of the Breast and Female Genital Organs (F. Tavassoli and M. Stratton, editors) in the World Health Organization series on histopathological and genetic criteria for classification of tumors. IARC Press. 2003

Principal Investigators
  • C. Blake Gilks
  • David Huntsman
  • Torsten Nielsen
  • Team
  • Christine Chow
  • Dave Voduc
  • Dongxia (Doris) Gao
  • Jennifer Choo
  • Niki Boyd
  • Samuel Leung
  • Sherman Lau
  • Alumni
  • Alessandro DeLuca
  • Andy Chan
  • Ashish Rajput
  • Blaise Clarke
  • Challayne Smith
  • Cindy Ruttan
  • Diana Ionescu
  • Dmitry Turbin
  • Dustin Thomson
  • Edward Lee
  • Erika Mehl
  • Erika Yorida
  • Hamid Masoudi
  • Jen Born
  • Jenny Cromarty
  • Jon Carrick
  • Krista Marcon
  • Maggie Cheang
  • Martin Koebel
  • Melinda Miller
  • Nicholas Au
  • Nikita Makretsov
  • Sonja Steigen
  • Steve Kalloger
  • Vlady Pavlova
  • spacer
    Copyright © 2014 Genetic Pathology Evaluation Centre All Rights Reserved; Last modified March 28, 2014